Denali Therapeutics (DNLI) Income towards Parent Company: 2017-2024
Historic Income towards Parent Company for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Income towards Parent Company rose 4.01% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
- As of Q4 2024, Denali Therapeutics' Income towards Parent Company stood at -$114.7 million, which was down 6.99% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' 5-year Income towards Parent Company high stood at $244.9 million for Q4 2020, and its period low was -$119.5 million during Q4 2023.
- For the 3-year period, Denali Therapeutics' Income towards Parent Company averaged around -$99.6 million, with its median value being -$102.6 million (2022).
- In the last 5 years, Denali Therapeutics' Income towards Parent Company skyrocketed by 553.28% in 2020 and then plummeted by 130.73% in 2021.
- Quarterly analysis of 5 years shows Denali Therapeutics' Income towards Parent Company stood at $244.9 million in 2020, then plummeted by 130.73% to -$75.3 million in 2021, then tumbled by 31.11% to -$98.7 million in 2022, then declined by 21.07% to -$119.5 million in 2023, then climbed by 4.01% to -$114.7 million in 2024.
- Its Income towards Parent Company was -$114.7 million in Q4 2024, compared to -$107.2 million in Q3 2024 and -$99.0 million in Q2 2024.